Latest Conference Articles

This analysis presented at AAAAI suggests that the experimental OMIT delivery of allergens via toothpaste may allow for a safer alternative to other immunotherapies.

Hosts break down their favorite sessions at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes.

Deepak Bhatt, MD, MPH, looks ahead to discuss what he is most excited about from the upcoming late-breaking clinical trials sessions at the American College of Cardiology 2024 annual meeting

These new data from BioCryst, presented at AAAAI, suggest that patients treated with berotralstat may see substantial decreases in HAE attacks.

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

In an interview during the 2024 AAAAI conference, Casale addressed his team’s findings regarding epinephrine nasal spray and its effectiveness with regard to exacerbations of urticaria.

These findings may allow for patients with severe allergic reactions to have an alternative to epinephrine auto-injector devices.

Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.

Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.

Rilzabrutinib, an oral BTK inhibitor, demonstrates efficacy in reducing itch and disease activity among patients with chronic spontaneous urticaria in phase 2 dose-ranging trial at AAAAI 2024.

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.

These findings, to be presented at AAAAI, may help to expand upon clinicians’ awareness of the mechanics of air pollution’s effect on asthma.

The MANDARA trial results, published in NEJM, show benralizumab's noninferiority to mepolizumab in eosinophilic granulomatosis with polyangiitis, with potential for oral glucocorticoid discontinuation.

This analysis, to be presented at AAAAI, suggests that adolescents’ attendance of daycare may lead to decreased IgE levels and diminished food and aeroallergen sensitization rates.

This analysis suggests that the financial burden of oral food challenges may be offset slightly through the use of FPIES.

These data, to be presented at AAAAI, indicate that following 12 and 24 months of immunotherapy with BMOIT, desensitization to milk products can be observed among patients.

These findings, to be presented at AAAAI, highlight the importance of labeling different cleansing products used by consumers with eczema.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

More than half of patients received return-IBD care via telehealth in the post-COVID period, and those with longer drive times were more likely to continue telehealth care.

This interview segment with Bhatia featured a discussion on addressing both unmet needs and lack of awareness among patients with actinic keratosis.

Bhatia discussed some of the major takeaways from his Winter Clinical presentation titled ‘What's New and Hot in AK Management.’

In this interview, Del Rosso spoke on takeaways from his conference talk ‘What's New in the Medicine Chest? Acne, Rosacea, Actinic Keratoses, Psoriasis, Urticaria and Other Common Dermatoses.’

During this segment of his interview, Eingun James Song, MD, spoke about upcoming treatments for psoriasis and personalizing care for patients.

In this subgroup analysis data shown at Winter Clinical, findings indicated IGA success with topical roflumilast foam among seborrheic dermatitis patients.

In this discussion with E. James Song, MD, several unique clinical pearls for those in dermatology were described and had been drawn from Song’s Winter Clinical presentation.

Keli Coleman, MD, discusses findings from her research about the role of pain scores and opioids in predicting hospitalization and return visits in children with sickle cell disease and uncomplicated pain crises.

Presented at ASH 2023, a new study demonstrated physical activity does not increase bleeding for patients with hemophilia A as patients with low physical activity still experienced frequent bleeding.

Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.